Fig. 5.

Long term relapse inhibition following a short course of ocrelizumab.

People with MS were treated on day 1 and day 15 with placebo or 600 mg ocrelizumab and repeated at week 24 as a double injection; at week 48 all participants were switched to a single injection of 600 mg ocrelizumab that was repeated at week 72 Hauser et al., 2013. The results represent the reported adjusted annualized relapse rate at week 48 (placebo-controlled), week 96 (cross-over and extension) and week 144, following an 18 month drug free period (Hughes, 2013).